<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            E Kevin Heist, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Samuel Lévy, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hugh Calkins, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 25, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial studies suggested that angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and (possibly) aldosterone antagonists might either prevent new onset and recurrent atrial fibrillation (AF) or reduce the rate of major adverse cardiovascular outcomes in these patients. However, the available data do not support the use of these drugs solely for these purposes.
        </p>
        <p>
         In this topic, ACE inhibitors and ARBs collectively will be referred to as "angiotensin inhibition."
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          POSSIBLE MECHANISMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mechanisms proposed to explain the benefit of angiotensin blockade found in the early studies included the direct effects of angiotensin blockade on the structural and electrical properties of the atria, as well as the indirect influence of improved control of heart failure and hypertension (in patients with these conditions), both of which are known risk factors for atrial fibrillation (AF) [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1014.html" rel="external">
          "The electrocardiogram in atrial fibrillation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1004.html" rel="external">
          "Epidemiology, risk factors, and prevention of atrial fibrillation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3481.html" rel="external">
          "Pathophysiology of heart failure: Neurohumoral adaptations", section on 'Renin-angiotensin system'
         </a>
         .)
        </p>
        <p>
         The following observations supported the proposed mechanisms:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduction in atrial stretch — Atrial stretch, due to increased left atrial (LA) pressure, is associated with changes in the refractory period and conduction properties of atrial myocardium. These abnormalities provide both potential triggers and the substrate for the initiation and perpetuation of AF. The hemodynamic effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) result in improved ventricular function and also reductions in LA pressure and wall stress [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention of atrial fibrosis — Fibrosis in the atrial myocardium may be an important component of the substrate necessary for AF. Atrial fibrosis is stimulated by elevated levels of angiotensin-II [
         <a href="#rid3">
          3
         </a>
         ] and reduced by treatment with ACE inhibitors [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention of electrical remodeling and direct antiarrhythmic effects — Direct effects of angiotensin blockade on ion channels and electrophysiologic properties have been suggested [
         <a href="#rid6">
          6
         </a>
         ], but data from both animal and human studies have been conflicting and inconclusive. Canine work has suggested direct inhibition of triggering of atrial arrhythmias by ACE inhibitors and ARBs [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PREVENTION OF NEW ONSET AF
         </span>
         <span class="headingEndMark">
          —
         </span>
         Post-hoc analyses of randomized trials and observations from nonrandomized studies have suggested that angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) reduce the incidence of new atrial fibrillation (AF) in a variety of settings including the treatment of left ventricular dysfunction or hypertension, and after coronary artery bypass graft surgery (CABG).
        </p>
        <p>
         The following findings were noted in a 2010 meta-analysis of data from 26 randomized trials [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ACE inhibitors and ARBs significantly reduced the risk of the development of AF (Odds Ratio [OR] 0.65, 95% CI 0.55-0.76); the benefit was equivalent with the two classes of drugs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The benefit of ACE inhibitors and ARBs appeared large in patients with systolic heart failure (OR 0.50), but the result was not statistically significant (95% CI 0.19-1.16).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The effect of ACE inhibitors and ARBs was greater in preventing recurrent AF (OR 0.45, 95% CI 0.31-0.65) compared to new-onset AF (OR 0.80, 95% CI 0.70-0.92)
        </p>
        <p>
        </p>
        <p>
         However, the strength of the conclusions from the meta-analysis is weakened due the inclusion of post hoc analyses of randomized trials performed for reasons other than prevention of AF (eg, heart failure, post-myocardial infarction [MI], or hypertension), heterogeneity, and the likely presence of publication or ascertainment bias.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Left ventricular dysfunction or heart failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the TRACE trial of patients with left ventricular dysfunction and sinus rhythm after an acute myocardial infarction,
         <a class="drug drug_general" data-topicid="10171" href="/z/d/drug information/10171.html" rel="external">
          trandolapril
         </a>
         therapy was associated with a significantly reduced incidence of subsequent AF at two- to four-year follow-up (2.8 versus 5.3 percent with placebo) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Similar findings were noted in retrospective analyses from the randomized trials SOLVD and Val-HeFT, which enrolled patients with chronic left ventricular dysfunction, almost all of whom had ischemic heart disease [
         <a href="#rid10">
          10,11
         </a>
         ]. In the SOLVD trial,
         <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">
          enalapril
         </a>
         significantly reduced the incidence of subsequent AF at a mean follow-up of 2.9 years (5.4 versus 24 percent with placebo, hazard ratio 0.22). (See
         <a class="medical medical_review" href="/z/d/html/71.html" rel="external">
          "Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials"
         </a>
         .)
        </p>
        <p>
         A smaller reduction in the incidence of new AF with the ARB
         <a class="drug drug_general" data-topicid="8670" href="/z/d/drug information/8670.html" rel="external">
          candesartan
         </a>
         was noted in the CHARM trials [
         <a href="#rid12">
          12
         </a>
         ]. Among 7601 patients enrolled in the three trials, 6379 patients did not have AF at baseline. At a median follow-up of 38 months, candesartan produced a reduction in the incidence of new AF (5.6 versus 6.7 percent, adjusted P value 0.039).
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some [
         <a href="#rid13">
          13-17
         </a>
         ], but not all [
         <a href="#rid18">
          18-20
         </a>
         ], studies comparing ACE inhibitors or ARBs to other classes of drugs in patients with hypertension have shown a lowering of the risk of development AF. A 2010 meta-analysis of trials with substantial heterogeneity found no significant reduction in the risk for AF [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         The role of angiotensin blockade in the treatment of hypertension is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">
          "Choice of drug therapy in primary (essential) hypertension"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H621977831">
         <span class="h2">
          Patients with other risk factors for atrial fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The issue of whether these therapies might prevent the development of AF in patients with risk factors other than left ventricular dysfunction, heart failure, or hypertension, such as diabetes or coronary artery disease, has not been well studied. (See
         <a class="medical medical_review" href="/z/d/html/1004.html" rel="external">
          "Epidemiology, risk factors, and prevention of atrial fibrillation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Coronary artery bypass graft
         </span>
         <span class="headingEndMark">
          —
         </span>
         The possible role of these therapies for the prevention of AF in patients undergoing cardiac surgery is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">
          "Atrial fibrillation and flutter after cardiac surgery", section on 'Ineffective or possibly effective therapies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          PREVENTION OF RECURRENT AF
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple small studies have demonstrated reduction in recurrent atrial fibrillation (AF) with use of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), but these findings have not been confirmed in larger, better powered studies.
        </p>
        <p>
         In small trials that enrolled fewer than 200 patients, ACE inhibitors or ARBs in combination with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         reduced the rate of recurrent AF compared with amiodarone alone [
         <a href="#rid22">
          22-26
         </a>
         ]. A small study of
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          ramipril
         </a>
         versus placebo in hypertensive patients demonstrated reduced AF recurrence with ramipril [
         <a href="#rid26">
          26
         </a>
         ] and a small randomized study comparing
         <a class="drug drug_general" data-topicid="10275" href="/z/d/drug information/10275.html" rel="external">
          telmisartan
         </a>
         to
         <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">
          carvedilol
         </a>
         in hypertensive patients with prior AF demonstrated less recurrence of AF in patients treated with telmisartan, despite similar blood pressure reduction between the two agents [
         <a href="#rid27">
          27
         </a>
         ]. However, these results from smaller studies were not confirmed in the GISSI-AF trial, which randomly assigned 1442 patients with a history of symptomatic AF and in sinus rhythm to receive either
         <a class="drug drug_general" data-topicid="10036" href="/z/d/drug information/10036.html" rel="external">
          valsartan
         </a>
         or placebo [
         <a href="#rid28">
          28
         </a>
         ]. All patients had underlying cardiovascular disease, diabetes, or left atrial enlargement.
        </p>
        <p>
         GISSI-AF found that
         <a class="drug drug_general" data-topicid="10036" href="/z/d/drug information/10036.html" rel="external">
          valsartan
         </a>
         did NOT prevent recurrent AF. At one-year follow-up, there was no significant difference between valsartan or placebo in the proportion of patients who had more than one episode of AF (51 versus 52 percent, adjusted hazard ratio 0.97, 95% CI 0.83-1.14) or in the median time from randomization to the first recurrence of AF (295 versus 291 days). Although 57 percent of patients were taking an ACE inhibitor and 70 percent were taking antiarrhythmic drugs at baseline that were continued throughout the trial and might have confounded the results, the outcomes in subgroup analysis were similar in the patients who were or were not being treated with such agents.
        </p>
        <p>
         Another possible contributor to the lack of benefit in GISSI-AF was a low prevalence of heart failure/left ventricular dysfunction (8 percent), since the meta-analysis cited above found that the benefit was greatest in patients with these conditions [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Prevention of recurrent AF with
         <a class="drug drug_general" data-topicid="8640" href="/z/d/drug information/8640.html" rel="external">
          irbesartan
         </a>
         was also analyzed in the ACTIVE I study, which randomized 9016 patients with a history of AF, stroke risk factors and a systolic blood pressure of at least 110 mm Hg to either irbesartan 300 mg once daily or placebo. Patients who received irbesartan in ACTIVE I were not significantly more likely to be in sinus rhythm at subsequent follow-up, regardless of whether they were initially in AF at baseline or in sinus rhythm at baseline (RR 0.97, p = 0.61). Similarly, the ANTIPAF study, a randomized study of placebo versus
         <a class="drug drug_general" data-topicid="10061" href="/z/d/drug information/10061.html" rel="external">
          olmesartan
         </a>
         in patients with documented paroxysmal AF, demonstrated no benefit in regard to recurrent AF episodes in patients randomized to olmesartan [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H615512240">
         <span class="h2">
          Aldosterone inhibition and atrial fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are data from animal and human studies to suggest that
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         , an aldosterone antagonist, may reduce the risk of recurrent AF [
         <a href="#rid31">
          31,32
         </a>
         ]. Supportive studies of specific drugs are summarized as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">
          Eplerenone
         </a>
         <strong>
         </strong>
         – A newer aldosterone antagonist, eplerenone, was shown in the randomized EMPHASIS-HF study to reduce new onset AF in patients with systolic heart failure and mild heart failure symptoms [
         <a href="#rid33">
          33
         </a>
         ]. Eplerenone was also shown in a small study to decrease AF recurrence after catheter ablation for long-standing persistent AF [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          Spironolactone
         </a>
         <strong>
         </strong>
         – In the TOPCAT randomized trial of spironolactone in patients with heart failure with preserved ejection fraction, spironolactone did not reduce the incidence of AF [
         <a href="#rid35">
          35
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">
          "Treatment and prognosis of heart failure with preserved ejection fraction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">
          "Treatment and prognosis of heart failure with preserved ejection fraction", section on 'Mineralocorticoid receptor antagonists'
         </a>
         ). A 2016 meta-analysis did suggest reduced AF in patients treated with aldosterone antagonists based on three randomized controlled trials and two observations studies, although this effect was evident for
         <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">
          eplerenone
         </a>
         but not spironolactone [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="132042" href="/z/d/drug information/132042.html" rel="external">
          Finerenone
         </a>
         <strong>
         </strong>
         – In a secondary analysis of the randomized FIDELIO-DKD trial of patients with chronic kidney disease and type 2 diabetes, those assigned the mineralocorticoid receptor antagonist finerenone resulted in a lower incidence of new-onset atrial fibrillation or flutter compared with placebo (hazard ratio 0.71; 95% CI 0.53-0.94) [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Meta analysis of aldosterone-antagonists
         </strong>
         – A 2019 meta-analysis of 24 studies (representing both randomized and observational studies, with a total of 7914 patients) demonstrated a significant reduction in AF occurrence in aldosterone-antagonist-treated patients compared with control patients (odds ratio 0.55; 95% CI 0.44-0.70), with significant AF reduction demonstrated in randomized and observational studies, and regardless of the particular aldosterone antagonist used [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Although there appears to be potential benefit to the use of aldosterone inhibitors in heart failure patients, we do not recommend aldosterone inhibitors specifically for prevention of new or recurrent AF. The details of mineralocorticoid receptor antagonists in heart failure are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">
          "Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Primary components of therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H615512079">
         <span class="h2">
          Catheter ablation of atrial fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The data are mixed as to whether ACE inhibitors/ARBs reduce AF after radiofrequency catheter ablation procedures: A significant benefit was seen in some [
         <a href="#rid39">
          39
         </a>
         ], but not other [
         <a href="#rid40">
          40,41
         </a>
         ] studies. (See
         <a class="medical medical_review" href="/z/d/html/949.html" rel="external">
          "Atrial fibrillation: Catheter ablation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H110572908">
         <span class="h1">
          PREVENTION OF CARDIOVASCULAR EVENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         As discussed in the sections on prevention above, the benefit of either angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blockers (ARB) therapy for the prevention of new or recurrent atrial fibrillation (AF) is uncertain. The issue of whether ARB therapy can reduce the rate of major adverse cardiovascular events in patients with AF was addressed in the ACTIVE I trial, which enrolled individuals with either permanent AF or at least two episodes of intermittent AF (in the previous six months) from the ACTIVE A and ACTIVE W trials [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="local">
          'Prevention of recurrent AF'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants", section on 'Introduction'
         </a>
         .)
        </p>
        <p>
         Mean reductions in systolic and diastolic blood pressures were 2.9 and 1.9 mmHg greater in the
         <a class="drug drug_general" data-topicid="8640" href="/z/d/drug information/8640.html" rel="external">
          irbesartan
         </a>
         group. At a mean follow-up of 4.1 years, there was no significant difference in the rates of the first combined coprimary outcome of stroke, myocardial infarction, or death from vascular causes for the irbesartan compared with placebo groups (5.4 percent per 100 person-years in both groups), and there was no significant difference in the rates of the second combined coprimary outcome, which included the components of the first coprimary outcome plus the rate of hospitalization for heart failure (7.3 and 7.7 percent per 100 person-years in the two groups, respectively).
        </p>
        <p>
         A Swedish registry study of patients followed after acute myocardial infarction showed that use of ACE inhibitors and ARBs did reduce all-cause mortality, but did not reduce the incidence of new-onset AF [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2908013410">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">
          "Society guideline links: Atrial fibrillation"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">
          "Society guideline links: Arrhythmias in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of atrial fibrillation
         </strong>
         – For patients at risk for atrial fibrillation (AF) but without another indication for angiotensin blockade, we recommend
         <strong>
          not
         </strong>
         initiating therapy with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker solely to prevent new onset AF (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Prevention of new onset AF'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of AF recurrence
         </strong>
         – In patients with a history of AF, we recommend NOT treating with an ACE inhibitor or ARB for the sole purpose of preventing recurrent AF (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Prevention of recurrent AF'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006; 27:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Webster MW, Fitzpatrick MA, Nicholls MG, et al. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 1985; 56:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McEwan PE, Gray GA, Sherry L, et al. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998; 98:2765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104:2608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakabe M, Fujiki A, Nishida K, et al. Enalapril prevents perpetuation of atrial fibrillation by suppressing atrial fibrosis and over-expression of connexin43 in a canine model of atrial pacing-induced left ventricular dysfunction. J Cardiovasc Pharmacol 2004; 43:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101:2612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sicouri S, Cordeiro JM, Talarico M, Antzelevitch C. Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol 2011; 22:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Zhang P, Mu Y, et al. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Pharmacol Ther 2010; 88:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107:2926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaer BA, Schneider C, Jick SS, et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med 2010; 152:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           L'Allier PL, Ducharme A, Keller PF, et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004; 44:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heckbert SR, Wiggins KL, Glazer NL, et al. Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. Am J Hypertens 2009; 22:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamashita T, Inoue H, Okumura K, et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011; 13:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider MP, Hua TA, Böhm M, et al. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010; 55:2299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24:2090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006; 27:1841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006; 47:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belluzzi F, Sernesi L, Preti P, et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009; 53:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galzerano D, Di Michele S, Paolisso G, et al. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. J Renin Angiotensin Aldosterone Syst 2012; 13:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           GISSI-AF Investigators, Disertori M, Latini R, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360:1606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45:1832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goette A, Schön N, Kirchhof P, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 2012; 5:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao J, Li J, Li W, et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 2010; 159:1584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dabrowski R, Borowiec A, Smolis-Bak E, et al. Effect of combined spironolactone-β-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am J Cardiol 2010; 106:1609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swedberg K, Zannad F, McMurray JJ, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59:1598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito Y, Yamasaki H, Naruse Y, et al. Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation. Am J Cardiol 2013; 111:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cikes M, Claggett B, Shah AM, et al. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. JACC Heart Fail 2018; 6:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu T, Korantzopoulos P, Shao Q, et al. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis. Europace 2016; 18:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filippatos G, Bakris GL, Pitt B, et al. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol 2021; 78:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexandre J, Dolladille C, Douesnel L, et al. Effects of Mineralocorticoid Receptor Antagonists on Atrial Fibrillation Occurrence: A Systematic Review, Meta-Analysis, and Meta-Regression to Identify Modifying Factors. J Am Heart Assoc 2019; 8:e013267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klemm HU, Heitzer T, Ruprecht U, et al. Impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the long-term outcome after pulmonary vein isolation for paroxysmal atrial fibrillation. Cardiology 2010; 117:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richter B, Derntl M, Marx M, et al. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 2007; 153:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al Chekakie MO, Akar JG, Wang F, et al. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol 2007; 18:942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACTIVE I Investigators, Yusuf S, Healey JS, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011; 364:928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batra G, Lindhagen L, Andell P, et al. Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Are Associated With Improved Outcome but Do Not Prevent New-Onset Atrial Fibrillation After Acute Myocardial Infarction. J Am Heart Assoc 2017; 6.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 935 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16311236" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2994451" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Effect of enalapril on ventricular arrhythmias in congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9851965" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11714658" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15167279" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Enalapril prevents perpetuation of atrial fibrillation by suppressing atrial fibrosis and over-expression of connexin43 in a canine model of atrial pacing-induced left ventricular dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10840013" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21159010" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20811347" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10421597" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12771010" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15864246" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16838426" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20083826" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15234426" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11937178" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15734615" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19265792" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10030325" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10577635" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21148662" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20488299" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12119249" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14643269" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16825288" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16424784" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Losartan and prevention of atrial fibrillation recurrence in hypertensive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19118720" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22546623" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19369667" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Valsartan for prevention of recurrent atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15936615" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22157519" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20082611" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21094362" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Effect of combined spironolactone-β-blocker±enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22538330" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23340033" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30007557" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26705563" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34015478" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31711383" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Effects of Mineralocorticoid Receptor Antagonists on Atrial Fibrillation Occurrence: A Systematic Review, Meta-Analysis, and Meta-Regression to Identify Modifying Factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20881389" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the long-term outcome after pulmonary vein isolation for paroxysmal atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17174648" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17593228" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21388310" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Irbesartan in patients with atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28320744" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Are Associated With Improved Outcome but Do Not Prevent New-Onset Atrial Fibrillation After Acute Myocardial Infarction.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
